Anixa Biosciences, Inc.
ANIX
$3.38
-$0.17-4.79%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.37% | -10.44% | 12.02% | -4.40% | 3.56% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 200.00% | -75.00% | -7.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 47.03% | -20.53% | -21.32% | 1.56% | -0.49% |
| Change in Net Operating Assets | 127.83% | -151.70% | 260.30% | -234.29% | 254.79% |
| Cash from Operations | 48.24% | -213.27% | 64.93% | -81.52% | 36.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.36% | 211.76% | -68.17% | 389.93% | 331.01% |
| Cash from Investing | -13.36% | 211.76% | -68.17% | 389.93% | 331.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -93.73% | 4,516.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -112.23% | 408.89% | 97.95% | -200.00% |
| Cash from Financing | 205.88% | -116.04% | -28.86% | -83.39% | -60.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 493.12% | -573.91% | -80.00% | 7,766.67% | -103.61% |